FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
This project shall be implemented through incorporation of a new joint venture company in Zambia
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
Subscribe To Our Newsletter & Stay Updated